PMID- 35170493
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20230914
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 79
IP  - 6
DP  - 2022 Jun 1
TI  - Effect of IL-1 Blockade With Anakinra on Heart Failure Outcomes in Patients With 
      Anterior Versus Nonanterior ST Elevation Myocardial Infarction.
PG  - 774-780
LID - 10.1097/FJC.0000000000001240 [doi]
AB  - Patients with ST elevation myocardial infarction (STEMI) are at risk of future 
      heart failure (HF), particularly those with anterior STEMI. Interleukin-1 (IL-1) 
      is a key mediator of the inflammatory response, and its blockade has emerged as a 
      potential therapeutic strategy to prevent HF events. The aim of this analysis was 
      to explore the effects of anakinra, an IL-1 receptor antagonist, on HF outcomes 
      based on anterior versus nonanterior location STEMI and to explore whether this 
      effect is mediated through the amelioration of left ventricular systolic function 
      and cardiac remodeling. We pooled data from 3 early phase randomized clinical 
      trials. The primary end point was a composite of all-cause death and new-onset HF 
      at 1-year follow-up. The left anterior descending coronary artery as culprit 
      vessel was used to identify anterior STEMI. We included 139 patients, 47 (34%) 
      with anterior STEMI and 92 (66%) with nonanterior STEMI. Anakinra significantly 
      reduced the combined end point of death or new-onset HF in patients with anterior 
      STEMI [4 (13%) vs. 7 (42%), log-rank P value = 0.049] and in patients with 
      nonanterior STEMI [3 (6%) vs. 9 (24%), log-rank P value = 0.014]. We found no 
      significant differences comparing anakinra versus placebo in interval changes in 
      left ventricular ejection fraction and volumes in anterior and nonanterior STEMI. 
      In conclusion, anakinra is associated with a reduction of HF events in patients 
      with STEMI, irrespective of anterior or nonanterior location, or of changes in 
      left ventricular ejection fraction or cardiac remodeling.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Del Buono, Marco Giuseppe
AU  - Del Buono MG
AD  - VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
AD  - Department of Cardiovascular and Pulmonary Sciences, Catholic University of the 
      Sacred Heart, Rome, Italy.
FAU - Damonte, Juan Ignacio
AU  - Damonte JI
AD  - VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
AD  - Interventional Cardiology Department, Hospital Italiano de Buenos Aires, 
      Argentina.
FAU - Chiabrando, Juan Guido
AU  - Chiabrando JG
AD  - VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
AD  - Interventional Cardiology Department, Hospital Italiano de Buenos Aires, 
      Argentina.
FAU - Markley, Roshanak
AU  - Markley R
AD  - VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
FAU - Turlington, Jeremy
AU  - Turlington J
AD  - VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
FAU - Trankle, Cory R
AU  - Trankle CR
AD  - VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
FAU - Kang, Le
AU  - Kang L
AD  - Department of Biostatistics, Virginia Commonwealth University, Richmond, VA.
FAU - Biondi-Zoccai, Giuseppe
AU  - Biondi-Zoccai G
AD  - Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University 
      of Rome, Latina, Italy.
AD  - Mediterranea Cardiocentro, Napoli, Italy.
FAU - Van Tassell, Benjamin W
AU  - Van Tassell BW
AD  - VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
AD  - Department of Pharmacotherapy and Outcomes Sciences, Virginia Commonwealth 
      University, Richmond, VA; and.
FAU - Abbate, Antonio
AU  - Abbate A
AD  - VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
AD  - Wright Center for Clinical and Translational Research, Virginia Commonwealth 
      University, Richmond, VA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00789724
GR  - KL2 RR031989/RR/NCRR NIH HHS/United States
GR  - R34 HL121402/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220601
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
RN  - 0 (Interleukin-1)
SB  - IM
MH  - *Heart Failure/diagnosis/drug therapy/etiology
MH  - Humans
MH  - Interleukin 1 Receptor Antagonist Protein/adverse effects
MH  - Interleukin-1
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - *ST Elevation Myocardial Infarction/diagnostic imaging/drug therapy
MH  - Stroke Volume
MH  - Ventricular Function, Left
MH  - Ventricular Remodeling
PMC - PMC9177574
MID - NIHMS1779346
COIS- A. Abbate and B. W. Van Tassell have served as consultants to Swedish Orphan 
      Biovitrum LLC in the past. G. Biondi-Zoccai has consulted for Cardionovum, 
      CrannMedical, InnovHeart, Meditrial, Opsens Medical, and Replycare. The remaining 
      authors report no conflicts of interest.
EDAT- 2022/02/17 06:00
MHDA- 2022/06/09 06:00
PMCR- 2023/06/01
CRDT- 2022/02/16 08:42
PHST- 2021/12/01 00:00 [received]
PHST- 2022/01/22 00:00 [accepted]
PHST- 2022/02/17 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/02/16 08:42 [entrez]
PHST- 2023/06/01 00:00 [pmc-release]
AID - 00005344-202206000-00004 [pii]
AID - 10.1097/FJC.0000000000001240 [doi]
PST - epublish
SO  - J Cardiovasc Pharmacol. 2022 Jun 1;79(6):774-780. doi: 
      10.1097/FJC.0000000000001240.